t*******r
发帖数: 364 | 1 竞争太激烈了，感觉很内卷
The FDA has cleared Breyanzi to treat newly relapsed or refractory large B-
cell lymphoma, less than three months after Yescarta became the first CAR-T
to reach the second-line setting. (Bristol Myers Squibb ) | T*****0
发帖数: 1853 | 2 这个领域确实竞争很激烈，有没有懂行的比较一下哪个比较好，更有前途？
T
【在 t*******r 的大作中提到】
: 竞争太激烈了，感觉很内卷
: The FDA has cleared Breyanzi to treat newly relapsed or refractory large B-
: cell lymphoma, less than three months after Yescarta became the first CAR-T
: to reach the second-line setting. (Bristol Myers Squibb )
|
|
